alosetron (BioDeep_00000405747)

   


代谢物信息卡片


5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H,2H,3H,4H,5H-pyrido[4,3-b]indol-1-one

化学式: C17H18N4O (294.1480538)
中文名称: 阿洛司琼
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C
InChI: InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)

描述信息

A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AE - Serotonin receptor antagonists
C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
D005765 - Gastrointestinal Agents

同义名列表

3 个代谢物同义名

alosetron; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H,2H,3H,4H,5H-pyrido[4,3-b]indol-1-one; Alosetron HCL



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Min Chen, Tai-Chun Tang, Di Qin, Ling Yue, Hui Zheng. Pharmacologic Treatments for Irritable Bowel Syndrome: an Umbrella Systematic Review. Journal of gastrointestinal and liver diseases : JGLD. 2020 Jun; 29(2):199-209. doi: 10.15403/jgld-817. [PMID: 32530987]
  • Yasuo Itomi, Takahiro Tanaka, Kozo Matsushita, Toru Kawamura, Takuto Kojima, Kazuyoshi Aso, Shiho Matsumoto-Okano, Yasuhiro Tsukimi. Pharmacological evaluation of a novel corticotropin-releasing factor 1 receptor antagonist T-3047928 in stress-induced animal models in a comparison with alosetron. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 2020 05; 32(5):e13795. doi: 10.1111/nmo.13795. [PMID: 31970891]
  • Nadine El-Ayache, James J Galligan. 5-HT3 receptor signaling in serotonin transporter-knockout rats: a female sex-specific animal model of visceral hypersensitivity. American journal of physiology. Gastrointestinal and liver physiology. 2019 01; 316(1):G132-G143. doi: 10.1152/ajpgi.00131.2018. [PMID: 30359082]
  • Marion France, Emmalee Skorich, Mark Kadrofske, Greg M Swain, James J Galligan. Sex-related differences in small intestinal transit and serotonin dynamics in high-fat-diet-induced obesity in mice. Experimental physiology. 2016 Jan; 101(1):81-99. doi: 10.1113/ep085427. [PMID: 26381722]
  • Darshan V Chaudhary, Daxesh P Patel, Jaivik V Shah, Priyanka A Shah, Mallika Sanyal, Pranav S Shrivastav. Application of a UPLC-MS/MS method for the analysis of alosetron in human plasma to support a bioequivalence study in healthy males and females. Biomedical chromatography : BMC. 2015 Oct; 29(10):1527-34. doi: 10.1002/bmc.3454. [PMID: 25761551]
  • Suhreta Mujakovic, José Jm ter Linde, Niek J de Wit, Corine J van Marrewijk, Gerdine Aj Fransen, N Charlotte Onland-Moret, Robert Jf Laheij, Jean Wm Muris, Diederick E Grobbee, Melvin Samsom, Jan Bmj Jansen, André Knottnerus, Mattijs E Numans. Serotonin receptor 3A polymorphism c.-42C > T is associated with severe dyspepsia. BMC medical genetics. 2011 Oct; 12(?):140. doi: 10.1186/1471-2350-12-140. [PMID: 22014438]
  • Shilan Mozaffari, Hadi Esmaily, Roja Rahimi, Maryam Baeeri, Yara Sanei, Azar Asadi-Shahmirzadi, Mohammad-Hossein Salehi-Surmaghi, Mohammad Abdollahi. Effects of Hypericum perforatum extract on rat irritable bowel syndrome. Pharmacognosy magazine. 2011 Jul; 7(27):213-23. doi: 10.4103/0973-1296.84235. [PMID: 21969792]
  • Fumihiko Toyoshima, Tadayuki Oshima, Shigemi Nakajima, Jun Sakurai, Junji Tanaka, Toshihiko Tomita, Kazutoshi Hori, Takayuki Matsumoto, Hiroto Miwa. Serotonin transporter gene polymorphism may be associated with functional dyspepsia in a Japanese population. BMC medical genetics. 2011 Jun; 12(?):88. doi: 10.1186/1471-2350-12-88. [PMID: 21714874]
  • Robin C Spiller. Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome. Current opinion in pharmacology. 2011 Feb; 11(1):68-74. doi: 10.1016/j.coph.2011.02.005. [PMID: 21398180]
  • Kine Gregersen, Jørgen Valeur, Kristine Lillestøl, Livar Frøyland, Pedro Araujo, Gülen Arslan Lied, Arnold Berstad. Subjective food hypersensitivity: assessment of enterochromaffin cell markers in blood and gut lavage fluid. International journal of general medicine. 2011; 4(?):555-60. doi: 10.2147/ijgm.s18349. [PMID: 21887108]
  • Gerard Clarke, Peter Fitzgerald, John F Cryan, Eugene M Cassidy, Eamonn M Quigley, Timothy G Dinan. Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort. BMC gastroenterology. 2009 Jan; 9(?):6. doi: 10.1186/1471-230x-9-6. [PMID: 19154614]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • M Camilleri. Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 2007 Aug; 19 Suppl 2(?):40-5. doi: 10.1111/j.1365-2982.2007.00961.x. [PMID: 17620087]
  • Y A Saito, G R Locke, J M Zimmerman, G Holtmann, J P Slusser, M de Andrade, G M Petersen, N J Talley. A genetic association study of 5-HTT LPR and GNbeta3 C825T polymorphisms with irritable bowel syndrome. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 2007 Jun; 19(6):465-70. doi: 10.1111/j.1365-2982.2007.00905.x. [PMID: 17564628]
  • Ronald Mathison, Eldon Shaffer, Hans-Juergen Pfannkuche, David Earnest. Effects of tegaserod on bile composition and hepatic secretion in Richardson ground squirrels on an enriched cholesterol diet. Lipids in health and disease. 2006 Jun; 5(?):15. doi: 10.1186/1476-511x-5-15. [PMID: 16792807]
  • Shiho Okano, Hideaki Nagaya, Nobuhiro Inatomi. Novelty stress increases fecal pellet output in mongolian gerbils: effects of several drugs. Journal of pharmacological sciences. 2005 Aug; 98(4):411-8. doi: 10.1254/jphs.fp0050353. [PMID: 16079466]
  • Michael Camilleri. Pharmacogenomics and functional gastrointestinal disorders. Pharmacogenomics. 2005 Jul; 6(5):491-501. doi: 10.2217/14622416.6.5.491. [PMID: 16013999]
  • Kevin Koch, Corinne Campanella, Charlotte A Baidoo, Janet A Manzo, Vanessa Z Ameen, Kathryn E E Kersey. Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex). Digestive diseases and sciences. 2004 Aug; 49(7-8):1244-9. doi: 10.1023/b:ddas.0000037819.31817.7c. [PMID: 15387353]
  • K M Koch, B W Corrigan, J Manzo, C D James, R J Scott, A G Stead, K E Kersey. Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors. Alimentary pharmacology & therapeutics. 2004 Jul; 20(2):223-30. doi: 10.1111/j.1365-2036.2004.02031.x. [PMID: 15233703]
  • Massimo Bellini, Lucia Rappelli, Corrado Blandizzi, Francesco Costa, Cristina Stasi, Rocchina Colucci, Gino Giannaccini, Donatella Marazziti, Laura Betti, Stefano Baroni, Maria Gloria Mumolo, Santino Marchi, Mario Del Tacca. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. The American journal of gastroenterology. 2003 Dec; 98(12):2705-11. doi: 10.1111/j.1572-0241.2003.08669.x. [PMID: 14687821]
  • S G O'Brien, P Meinhardt, E Bond, J Beck, B Peng, C Dutreix, G Mehring, S Milosavljev, C Huber, R Capdeville, T Fischer. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. British journal of cancer. 2003 Nov; 89(10):1855-9. doi: 10.1038/sj.bjc.6601152. [PMID: 14612892]
  • E Scherl, C L Frissora. Irritable bowel syndrome genophenomics: correlation of serotonin-transporter polymorphisms and alosetron response. The pharmacogenomics journal. 2003; 3(2):64-6. doi: 10.1038/sj.tpj.6500163. [PMID: 12746730]
  • M Simrén, L Simms, D D'Souza, H Abrahamsson, E S Björnsson. Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors. Alimentary pharmacology & therapeutics. 2003 Jan; 17(2):279-87. doi: 10.1046/j.1365-2036.2003.01399.x. [PMID: 12534414]
  • Gareth A Hicks, Jonathan R Coldwell, Marcus Schindler, Philip A Bland Ward, David Jenkins, Penny A Lynn, Patrick P A Humphrey, L Ashley Blackshaw. Excitation of rat colonic afferent fibres by 5-HT(3) receptors. The Journal of physiology. 2002 11; 544(3):861-9. doi: 10.1113/jphysiol.2002.025452. [PMID: 12411529]
  • Michael Camilleri, Elena Atanasova, Paula J Carlson, Umraan Ahmad, H Jae Kim, Blanca E Viramontes, Sanna McKinzie, Raul Urrutia. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2002 Aug; 123(2):425-32. doi: 10.1053/gast.2002.34780. [PMID: 12145795]
  • K M Koch, J L Palmer, N Noordin, J J Tomlinson, C Baidoo. Sex and age differences in the pharmacokinetics of alosetron. British journal of clinical pharmacology. 2002 Mar; 53(3):238-42. doi: 10.1046/j.0306-5251.2001.01565.x. [PMID: 11874386]
  • K M Koch, B M Ricci, N S Hedayetullah, D Jewell, K E Kersey. Effect of alosetron on theophylline pharmacokinetics. British journal of clinical pharmacology. 2001 Nov; 52(5):596-600. doi: 10.1046/j.0306-5251.2001.01477.x. [PMID: 11736869]
  • R Borman. Serotonergic modulation and irritable bowel syndrome. Expert opinion on emerging drugs. 2001 Apr; 6(1):57-68. doi: 10.1517/14728214.6.1.57. [PMID: 15989496]
  • W Jiang, M E Kreis, C Eastwood, A J Kirkup, P P Humphrey, D Grundy. 5-HT(3) and histamine H(1) receptors mediate afferent nerve sensitivity to intestinal anaphylaxis in rats. Gastroenterology. 2000 Nov; 119(5):1267-75. doi: 10.1053/gast.2000.19461. [PMID: 11054384]
  • M Camilleri. Pharmacology and clinical experience with alosetron. Expert opinion on investigational drugs. 2000 Jan; 9(1):147-59. doi: 10.1517/13543784.9.1.147. [PMID: 11060667]
  • C P Bearcroft, E A André, M J Farthing. In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study. Alimentary pharmacology & therapeutics. 1997 Dec; 11(6):1109-14. doi: 10.1046/j.1365-2036.1997.d01-1389.x. [PMID: 9663837]
  • T L Lloyd, S K Gupta, A E Gooding, J R Alianti. Determination of alosetron in human plasma or serum by high-performance liquid chromatography with robotic sample preparation. Journal of chromatography. B, Biomedical applications. 1996 Apr; 678(2):261-7. doi: 10.1016/0378-4347(95)00491-2. [PMID: 8738030]
  • S K Gupta, R L Kunka, A Metz, T Lloyd, G Rudolph, J M Perel. Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. Journal of clinical pharmacology. 1995 Feb; 35(2):202-7. doi: 10.1002/j.1552-4604.1995.tb05012.x. [PMID: 7751433]
  • S A Wring, R M O'Neill, J L Williams, H L Birch, C P Goddard, P D Andrew, W N Jenner. Radioimmunoassay for the determination of alosetron in human urine and saliva. The Analyst. 1994 Nov; 119(11):2395-401. doi: 10.1039/an9941902395. [PMID: 7872486]